Several Indian pharmaceutical companies are preparing to introduce generic versions of the

几家印度制药公司正准备推出仿制版本的

diabetes drug

糖尿病药物

Empagliflozin at significantly lower prices. The move follows the expiration of Boehringer Ingelheim’s patent on March 11, industry sources told TOI.

恩格列净价格显著降低。业内消息人士告诉《印度时报》，此举是在勃林格殷格翰公司的专利3月11日到期之后采取的。

The launch of these cost-effective alternatives is expected to reduce the financial burden of diabetes treatment for millions of patients in India.

这些具有成本效益的替代品的推出预计将减轻印度数百万糖尿病患者的治疗经济负担。

Mankind Pharma

人类制药

, Torrent, Alkem, Dr Reddy’s, and

，Torrent、Alkem、Dr Reddy’s，以及

Lupin

鲁邦三世

are among the companies planning to introduce their versions soon.

计划很快推出各自版本的公司之中。

Pricing expected to drop sharply

预计价格将大幅下降

Mankind Pharma, India’s fourth-largest pharmaceutical firm by market share, plans to offer Empagliflozin at one-tenth of the innovator’s price of Rs 60 per tablet, according to sources. Most generic versions are expected to be priced between Rs 9 and Rs 14 per tablet, making diabetes therapy more accessible.

据消息人士透露，印度第四大制药公司Mankind Pharma计划以原研药每片60卢比价格的十分之一推出恩格列净。大多数仿制药版本预计每片定价在9至14卢比之间，这将使糖尿病治疗更加可及。

This price reduction could significantly impact India’s diabetes drug market, which has grown from Rs 14,000 crore in 2021 to nearly Rs 20,000 crore today..

这一价格下调可能对印度的糖尿病药物市场产生重大影响，该市场已从2021年的1.4万亿卢比增长到如今的近2万亿卢比。

Diabetes prevalence and financial burden

糖尿病患病率与经济负担

India has an estimated 10.1 crore people living with diabetes, according to the International Diabetes Federation. The financial strain is considerable, as most patients bear treatment costs out-of-pocket due to limited medical reimbursement options. Diabetes-related complications further increase expenses, making cost-effective treatment options crucial..

根据国际糖尿病联合会的数据，印度大约有1.01亿人患有糖尿病。由于医疗报销选项有限，大多数患者需自费承担治疗费用，经济压力相当大。糖尿病相关并发症进一步增加了开支，因此寻找经济实惠的治疗方案变得至关重要。

Pharmaceutical strategies and market outlook

制药策略与市场展望

Torrent Pharmaceuticals

Torrent制药公司

had already strengthened its position in this market by acquiring three Empagliflozin brands from Boehringer Ingelheim last year. Meanwhile, Mankind Pharma is focusing on affordability.

去年通过从勃林格殷格翰收购三个恩格列净品牌，已经加强了其在这一市场的地位。同时，Mankind Pharma正专注于药物的可负担性。

Artificial Intelligence(AI)

人工智能（AI）

Java Programming with ChatGPT: Learn using Generative AI

使用ChatGPT进行Java编程：通过生成式AI学习

By - Metla Sudha Sekhar, IT Specialist and Developer

作者 - Metla Sudha Sekhar，IT专家和开发者

View Program

查看程序

Artificial Intelligence(AI)

人工智能（AI）

Basics of Generative AI: Unveiling Tomorrows Innovations

生成式人工智能基础：揭示未来的创新

By - Metla Sudha Sekhar, IT Specialist and Developer

作者 - Metla Sudha Sekhar，IT专家和开发人员

View Program

查看程序

Artificial Intelligence(AI)

人工智能（AI）

Generative AI for Dynamic Java Web Applications with ChatGPT

使用ChatGPT的动态Java Web应用程序的生成式AI

By - Metla Sudha Sekhar, IT Specialist and Developer

作者 - Metla Sudha Sekhar，IT专家和开发人员

View Program

查看程序

Marketing

市场营销

Performance Marketing for eCommerce Brands

电子商务品牌的绩效营销

By - Zafer Mukeri, Founder- Inara Marketers

作者 - 扎费尔·穆凯里，创始人 - 伊纳拉营销公司

View Program

查看程序

Artificial Intelligence(AI)

人工智能（AI）

Mastering C++ Fundamentals with Generative AI: A Hands-On

掌握C++基础与生成式AI：实践指南

By - Metla Sudha Sekhar, IT Specialist and Developer

作者 - Metla Sudha Sekhar，IT专家和开发人员

View Program

查看程序

Finance

金融

A2Z Of Money

金钱的A到Z

By - elearnmarkets, Financial Education by StockEdge

作者 - elearnmarkets，StockEdge 提供的金融教育

View Program

查看程序

Artificial Intelligence(AI)

人工智能（AI）

Master in Python Language Quickly Using the ChatGPT Open AI

快速使用ChatGPT Open AI掌握Python语言

By - Metla Sudha Sekhar, IT Specialist and Developer

作者 - Metla Sudha Sekhar，IT专家和开发人员

View Program

查看程序

Office Productivity

办公生产力

Zero to Hero in Microsoft Excel: Complete Excel guide 2024

从零到英雄：2024完整Excel指南

By - Metla Sudha Sekhar, IT Specialist and Developer

作者 - Metla Sudha Sekhar，IT专家和开发人员

View Program

查看程序

Artificial Intelligence(AI)

人工智能（AI）

AI and Analytics based Business Strategy

基于人工智能和分析的商业战略

By - Tanusree De, Managing Director- Accenture Technology Lead, Trustworthy AI Center of Excellence: ATCI

作者 - Tanusree De，董事总经理 - 埃森哲技术主管，可信人工智能卓越中心：ATCI

View Program

查看程序

Technology

技术

Certified Jenkins Professional

认证的Jenkins专业人士

By - Vskills, India's Leading Certification Body

由Vskills提供，印度领先的认证机构

View Program

查看程序

Astrology

占星术

Vastu Shastra Course

风水课程

By - Sachenkumar Rai, Vastu Shashtri

作者 - 萨钦库马尔·赖，瓦斯图沙斯特里

View Program

查看程序

Data Science

数据科学

SQL for Data Science along with Data Analytics and Data Visualization

用于数据科学的SQL以及数据分析和数据可视化

By - Metla Sudha Sekhar, IT Specialist and Developer

作者 - Metla Sudha Sekhar，IT专家和开发者

View Program

查看程序

Web Development

网络开发

A Comprehensive ASP.NET Core MVC 6 Project Guide for 2024

2024年全面的ASP.NET Core MVC 6项目指南

By - Metla Sudha Sekhar, IT Specialist and Developer

作者 - Metla Sudha Sekhar，IT专家和开发人员

View Program

查看程序

Office Productivity

办公生产力

Mastering Microsoft Office: Word, Excel, PowerPoint, and 365

掌握 Microsoft Office：Word、Excel、PowerPoint 和 365

By - Metla Sudha Sekhar, IT Specialist and Developer

作者 - Metla Sudha Sekhar，IT专家和开发人员

View Program

查看程序

Marketing

市场营销

Digital marketing - Wordpress Website Development

数字营销 - WordPress网站开发

By - Shraddha Somani, Digital Marketing Trainer, Consultant, Strategiest and Subject Matter expert

作者 - Shraddha Somani，数字营销培训师、顾问、策略师和主题专家

View Program

查看程序

Web Development

网络开发

Mastering Full Stack Development: From Frontend to Backend Excellence

掌握全栈开发：从前端到后端的卓越之旅

By - Metla Sudha Sekhar, IT Specialist and Developer

作者 - Metla Sudha Sekhar，IT专家和开发人员

View Program

查看程序

Finance

金融

Financial Literacy i.e Lets Crack the Billionaire Code

金融知识，即让我们破解亿万富翁密码

By - CA Rahul Gupta, CA with 10+ years of experience and Accounting Educator

作者 - CA Rahul Gupta，拥有10年以上经验的特许会计师及会计教育家

View Program

查看程序

Leadership

领导力

Business Storytelling Masterclass

商业故事讲述大师班

By - Ameen Haque, Founder of Storywallahs

作者 - 阿明·哈克，Storywallahs创始人

View Program

查看程序

Marketing

市场营销

Future of Marketing & Branding Masterclass

营销与品牌塑造的未来大师班

By - Dr. David Aaker, Professor Emeritus at the Haas School of Business, UC Berkeley, Author | Speaker | Thought Leader | Branding Consultant

作者 - 大卫·艾克博士，加州大学伯克利分校哈斯商学院荣休教授，作家 | 演讲者 | 思想领袖 | 品牌顾问

View Program

查看程序

Strategy

策略

ESG and Business Sustainability Strategy

ESG与商业可持续发展战略

By - Vipul Arora, Partner, ESG & Climate Solutions at Sattva Consulting Author I Speaker I Thought Leader

作者：维普尔·阿罗拉，Sattva咨询公司ESG与气候解决方案合伙人，作者 | 演讲者 | 思想领袖

View Program

查看程序

“This aligns with our philosophy of breaking cost barriers with a high-quality product (raw materials certified by regulators like the USFDA) at an affordable price. Using our own active pharmaceutical ingredient in bulk lowers costs, and we will deploy separate teams to promote two distinct brands, boosting distribution and market share,” said a Mankind Pharma executive..

“这符合我们以实惠的价格提供高质量产品（经美国食品药品监督管理局等监管机构认证的原材料）打破成本壁垒的理念。大量使用我们自己的活性药物成分降低了成本，我们将部署不同的团队来推广两个不同的品牌，提升分销和市场份额，”曼金德制药的一位高管表示。

The Empagliflozin market, including its combination therapies, is valued at Rs 640 crore. The drug has been recognized for reducing hospitalizations related to heart failure, slowing chronic kidney disease progression, and improving survival rates in diabetic and non-diabetic patients. However, high costs have historically limited access..

恩格列净市场，包括其联合疗法，价值为64亿卢比。该药物已被认可用于减少与心力衰竭相关的住院治疗，减缓慢性肾病进展，并提高糖尿病和非糖尿病患者的生存率。然而，高昂的成本历来限制了其可及性。

Diabetes treatment landscape

糖尿病治疗领域

Metformin remains the primary treatment for type-2 diabetes, but as the disease advances, additional medications such as Sulfonylureas, DPP-4 Inhibitors, and SGLT2 Inhibitors—including Empagliflozin—are added. Recently, newer drugs like semaglutide and tirzepatide have entered the market, offering better glycemic control and cardiovascular benefits..

二甲双胍仍然是2型糖尿病的主要治疗方法，但随着疾病进展，会添加其他药物，如磺脲类药物、DPP-4抑制剂和SGLT2抑制剂（包括恩格列净）。最近，像司美格鲁肽和替西帕肽这样的新药已经进入市场，提供了更好的血糖控制和心血管益处。

The introduction of affordable Empagliflozin generics is expected to reshape India’s diabetes drug market, making treatment more accessible while intensifying competition among pharmaceutical firms.

预计价格实惠的恩格列净仿制药的推出将重塑印度的糖尿病药物市场，在使治疗更加可及的同时，加剧制药公司之间的竞争。

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)